Telo Genomics Corp (OP: TDSGF )

0.1295 -0.0065 (-4.78%)

Streaming Delayed Price Updated: 9:38 AM EDT, Jul 17, 2024 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	140
Open	0.1360
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	0.1360
Today's Range	0.1295 - 0.1295
52wk Range	0.0795 - 0.2372
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

EXCLUSIVE: Telo Genomics' Smoldering Multiple Myeloma Prognostic Test Predicts Risk Of Disease Progression, Study Shows

May 30, 2024

American Journal of Hematology accepts Telo Genomics' study on TeloViewSMM, a prognostic test for smoldering multiple myeloma. The test showed 85% positive and 73% negative predictive values, offering...

Via Benzinga

Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030

January 30, 2024

EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END

Via FinancialNewsMedia

Performance

YTD	-32.45%	-32.45%
1 Month	-9.31%	-9.31%
3 Month	-13.78%	-13.78%
6 Month	+2.78%	+2.78%
1 Year	-35.25%	-35.25%

More News

Telo Genomics Completes International Standards Organization ("ISO") 15189 Final Accreditation

October 26, 2023

Via Newsfile

Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030

January 30, 2024

From FN Media Group LLC

Via GlobeNewswire

Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030

October 17, 2023

Via FinancialNewsMedia

Telo Genomics Announces Clinical Launch of Non-Invasive Cancer Diagnostic, TeloViewSMM – An Important Commercial Milestone Achieved

October 17, 2023

Via FinancialNewsMedia

Telo Genomics Presents Positive Results in Assessing MRD in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting

October 12, 2023

Via FinancialNewsMedia

Telo Genomics Announces Achieving Interim Results from Smouldering Myeloma Clinical Study

September 14, 2022

Via Newsfile

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.